Device: Desktop
Opening
a new frontier
in pharmacology
Opening
a new frontier
a new frontier
in pharmacology
Opening
a new frontier
in pharmacology
A pipeline of pharmacological inhibitors
with a unique mechanism of action
Signaling Specific inhibitors
of the CB1 (CB1-SSi)
of the CB1 (CB1-SSi)
Targeting disease states of the brain while preserving normal behavior
AEF0117 for cannabis related disorders
AEF0217 for the treatment of cognitive deficits
Aelis Farma’s Mission
”
To combine the scientific breakthrough of CB1 with innovative drug development to provide new effective and safe treatments for brain diseases with unmet medical needs.
“
Pier Vincenzo Piazza, CEO
Latest News
Latest News
A New Chapter for Aelis Farma - Inauguration of New Headquarters in the Center of Bordeaux
December 2023
+
Aelis Farma announces positive results of non-clinical studies required by regulatory agencies to enter its first CB1-SSi, AEF0117, in phase 3 clinical trial...
November 2023
+